132 related articles for article (PubMed ID: 35696627)
21. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
[TBL] [Abstract][Full Text] [Related]
22. The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial.
Dosani M; Morris WJ; Tyldesley S; Pickles T
Clin Oncol (R Coll Radiol); 2017 Oct; 29(10):696-701. PubMed ID: 28712786
[TBL] [Abstract][Full Text] [Related]
23. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
24. Factors Predicting the Off-treatment Duration in Patients with Prostate Cancer Receiving Degarelix as Intermittent Androgen Deprivation Therapy.
Abrahamsson PA; Boccon-Gibod L; Morote J; de Jong IJ; Malmberg A; Neijber A; Albers P
Eur Urol Focus; 2017 Oct; 3(4-5):470-479. PubMed ID: 28753747
[TBL] [Abstract][Full Text] [Related]
25. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
Wang Y; Dai B; Ye DW
Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
[TBL] [Abstract][Full Text] [Related]
26. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
[TBL] [Abstract][Full Text] [Related]
27. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
28. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
29. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
Tremblay S; Summers-Trasiewicz L; Pouliot F; Crook JM; Ding K; Klotz L; Toren P
J Urol; 2021 Nov; 206(5):1166-1176. PubMed ID: 34184929
[TBL] [Abstract][Full Text] [Related]
30. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer.
Koontz BF; Hoffman KE; Halabi S; Healy P; Anand M; George DJ; Harrison MR; Zhang T; Berry WR; Corn PG; Lee WR; Armstrong AJ
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1271-1278. PubMed ID: 33259932
[TBL] [Abstract][Full Text] [Related]
31. Renal Function Improves After the Discontinuation of Androgen Deprivation Therapy in Japanese Patients With Prostate Cancer.
Masuda H; Fujimoto A; Kanesaka M; Hou K; Suyama T; Araki K; Kojima S; Naya Y
Anticancer Res; 2021 Sep; 41(9):4443-4446. PubMed ID: 34475067
[TBL] [Abstract][Full Text] [Related]
32. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
33. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
34. Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.
Nead KT; Gaskin G; Chester C; Swisher-McClure S; Dudley JT; Leeper NJ; Shah NH
J Clin Oncol; 2016 Feb; 34(6):566-71. PubMed ID: 26644522
[TBL] [Abstract][Full Text] [Related]
35. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
Perachino M; Cavalli V; Bravi F
BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
[TBL] [Abstract][Full Text] [Related]
36. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer.
Sharifi N; Hamada A; Sissung T; Danesi R; Venzon D; Baum C; Gulley JL; Price DK; Dahut WL; Figg WD
BJU Int; 2008 Aug; 102(5):617-21. PubMed ID: 18537956
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Impact of Serum Testosterone and Body Mass Index Before Androgen-deprivation Therapy in Metastatic Prostate Cancer.
Shiota M; Takeuchi A; Sugimoto M; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Yokomizo A
Anticancer Res; 2015 Dec; 35(12):6925-32. PubMed ID: 26637918
[TBL] [Abstract][Full Text] [Related]
38. A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy.
Klotz L; Loblaw A; Siemens R; Ouellette P; Kapoor A; Kebabdjian M; Zhang L; Saad F;
J Urol; 2018 Aug; 200(2):335-343. PubMed ID: 29534997
[TBL] [Abstract][Full Text] [Related]
39. Subcastrate Testosterone Nadir and Clinical Outcomes in Intermediate- or High-Risk Localized Prostate Cancer.
Bryant AK; McKay RR; Kader AK; Parsons JK; Einck JP; Kane CJ; Mundt AJ; Murphy JD; Rose BS
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1068-1076. PubMed ID: 30543857
[TBL] [Abstract][Full Text] [Related]
40. Quality of life in prostate cancer patients taking androgen deprivation therapy.
Dacal K; Sereika SM; Greenspan SL
J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]